INORGANIC ION EXCHANGERS FOR 213 BI GENERATORS

描述(逐字摘自申请人的摘要)：213Bi是一种短暂的， 阿尔法放射性核素已被确定为理想的核素 白血病和其他微转移癌症的治疗。临床 目前，这种同位素的应用受到供应有限的阻碍。 高纯~(213)Bi。首选的供电方式是发电机。 其中225Ac被固定在离子交换柱上，而213Bi被洗脱为 必填项。电流发生器使用有机离子交换树脂 易受辐射损伤，导致柱子堵塞和/或释放 热原和~(225)Ac进入~(213)Bi产物。这项提案将设计， 使用防辐射技术建造和测试先进的自动发电机 无机离子交换材料。发电机还将产生213Bi 适合于快速合成~(213)Bi的产物 放射性药物。现有的发电机通常在以下位置生产双乘积 Hi或HCl溶液，需要多步骤处理才能制造 放射性药物。这种最先进的发电机将推动 通过改善α-发射体在癌症治疗中的新兴领域 以合适的形式生产纯净的~(213)Bi的~(213)Bi发生器的可靠性 用于放射性药物制造和提高~(213)Bi的可用性 癌症研究人员。 建议的商业应用： 据设想，该发电机将用于医学研究中心和医院 治疗白血病和卵巢癌等癌症患者。它将允许Alpha 常规治疗，相信~(213)Bi产物将是纯净和 适用于放射性药物加工。自动发电机的设计也将 服从目前正在使用的其他发电系统(例如，99Mo/99Tc)。

DESCRIPTION (Verbatim from the Applicant's Abstract): 213Bi is a short-lived, alpha-emitting radionuclide that has been identified as an ideal isotope for the treatment of leukemia and other micrometastatic cancers. Clinical applications of this isotope are currently hindered by the limited supply of high purity 213Bi. The preferred method of supply is in the form of a generator in which 225Ac is immobilized on an ion exchange column and 213Bi is eluted as required. Current generators use organic ion exchange resins that are susceptible to radiation damage, leading to column blocking and/or the release of pyrogens and 225Ac into the 213Bi product. This proposal will design, construct and test an advanced, automated generator using radiation-resistant inorganic ion exchange materials. The generator will also produce the 213Bi product in a form suitable for the rapid synthesis of 213Bi radiopharmaceuticals. Existing generators typically produce the Bi product in HI or HCl solutions, which require multi-step processing to manufacture radiopharmaceuticals. This state-of-the art generator will fuel research in the fledgling field of alpha-emitters in cancer treatment by improving the reliability of the 213Bi generators, producing pure 213Bi in a suitable form for radiopharmaceutical manufacture and increasing the availability of 213Bi to cancer researchers. PROPOSED COMMERCIAL APPLICATION: It is envisioned that the generator will be used at medical research centers and hospitals to treat patients with cancers, such as leukemia and ovarian cancer. It will allow alpha therapy to be performed routinely with confidence that the 213Bi product will be pure and amenable for radiopharmaceutical processing. The automated generator design will also be amenable to other generator systems currently in use (e.g., 99Mo/99Tc).